Announcement PDF RNS Number : 5809M Shield Therapeutics PLC 12 January 2023 TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Shield Therapeutics plc 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) UK issuer 2. Reason for the notification (please mark the appropriate box or boxes with an "X") An acquisition or disposal of voting rights An acquisition or disposal of financial instruments An event changing the breakdown of voting rights x Other (please specify) iii: 3. Details of person subject to the notification obligation iv Name W. Health L.P. ("Inventages") City and country of registered office (if applicable) The Bahamas 4. Full name of shareholder(s) (if different from 3.) v Name CGWL Nominees Limited City and country of registered office (if applicable) London, UK 5. Date on which the threshold was crossed or reached vi : 6 January 2023 6. Date on which issuer notified (DD/MM/YYYY): 11 January 2023 7. Total positions of person(s) subject to the notification obligation % of voting rights at- tached to shares (to- tal of 8. A) % of voting rights through financial instru- ments (total of 8.B 1 + 8.B 2) Resulting situation on the date on which threshold was crossed or reached 9.56% 0% 9.56% Position of previous notification (if applicable) 21.76% 0% 21.76% Total of both in % (8.A + 8.B) Total number of voting rights held in issuer (8.A + 8.B) vii 56,008,541 8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii A: Voting rights attached to shares Class/type of shares ISIN code (if possible) Number of voting rights ix Direct Indirect % of voting rights Direct GB00BYV81293 56,008,541 9.56% (DTR5.1) (DTR5.2.1) 0 56,008,541 SUBTOTAL 8. A Indirect (DTR5.1) (DTR5.2.1) 0% 9.56% B 1: Financial Instruments according to DTR5.3.1R (1) (a) Type of financial instrument Expiration date x Exercise/ Conversion Period xi Number of voting rights that may be acquired if the instrument is exercised/converted. % of voting rights SUBTOTAL 8. B 1 B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b) Type of financial Expiration instrument date x Exercise/ Conversion Period xi Physical or cash Settlement xii SUBTOTAL 8.B.2 Number of voting rights % of voting rights Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii x Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv % of voting rights if it equals or is higher than the notifiable threshold Name xv % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold 10. In case of proxy voting, please identify: Name of the proxy holder The number and % of voting rights held The date until which the voting rights will be held Place of completion The Bahamas Date of completion 11 January 2023 This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END HOLBTMITMTTBBJJ